Alicia Irurzun-Lafitte is a Principal at M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany. She joined the fund in 2014 and is focused on early stage investments in Healthcare, primarily therapeutics. Alicia has been instrumental in the closing of multiple new investment such as Artios, Macrophage Therapeutics, Storm Therapeutics, Rewind Therapeutics and spin-offs creation. Prior to M Ventures, Alicia was responsible for search and evaluation efforts as well as transactions in Global Business Development at Merck Serono S.A. in Geneva. Alicia holds a Master of Research degree in Bio-pharmaceutical Sciences from Leiden University. Alicia is based in Boston.